Innogenetics Partners with PamGene

Innogenetics and PamGene International have announced an agreement whereby Innogenetics gains access to PamGene's microarray technology platform for the development of its next generation nucleic acid and protein-based tests.

By combining Innogenetics' expertise in developing and marketing specialty diagnostics and PamGene's advanced technology platform, multi parameter assays will be developed and updated rapidly, thus reducing their time-to-market. The exclusive license, secured by Innogenetics on PamGene's technology, covers the PamStation(TM) 12 dedicated instrumentation in those areas where Innogenetics is currently active (infectious diseases, genetic testing and neurodegeneration) with an optional extension for applications in the field of oncology.

Upon thorough evaluation of different technology alternatives, Innogenetics selected PamGene's advanced microarray technology as its platform combined with its PamStation(TM) 12 instrumentation. This approach allows Innogenetics to develop tests that can assess up to 400 different parameters in one sample run (a tenfold increase compared to Innogenetics' current LiPA and LIA technology). The first set of assays based on the new platform is expected to reach the market in 2006.